Zynerba Pharmaceuticals Announces Pricing for Initial Public Offering

Zynerba Pharmaceuticals Inc. announced the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14 per share, before underwriting discounts.
As quoted in the press release:

All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba’s common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol “ZYNE” on August 5, 2015.
Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc.are acting as co-managers for the offering. This offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388, or by email at Prospectus_Department@Jefferies.com, or by accessing the SEC’s website at www.sec.gov.
A registration statement on Form S-1 relating to these securities was declared effective by the Securities and Exchange Commission on August 4, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Click here to read the full Zynerba Pharmaceuticals press release.